Class: Anti-infective agent
- Powder for injection, lyophilized 500 mg
- Powder for injection, lyophilized 1 g
- Powder for injection, lyophilized 5 g
- Powder for injection, lyophilized 10 g
- Pulvules 125 mg
- Pulvules 250 mg
- Powder for injection 500 mg
- Powder for injection 10 g
- Powder for injection 500 mg
- Powder for injection 1 g
- Powder for injection 5 g
- Powder for oral solution 1 g
Inhibits bacterial cell wall synthesis and alters cell-membrane permeability and RNA synthesis.
Poorly absorbed (orally). C max is 63 mcg/mL. T max is 1 h.
55% protein bound. Vd is 0.3 to 0.43 L/kg. Distributes to pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and atrial appendage tissue.
No apparent metabolism of the drug.
Mean t ½ is 4 to 6 h. 75% is excreted in urine by glomerular filtration (in the first 24 h). Mean plasma Cl is 0.058 L/kg/h. Renal Cl is 0.048 L/kg/h.
Renal Function Impairment
Renal function impairment slows excretion of vancomycin in anephric patients, t ½ is 7.5 days.
Total systemic and renal Cl may be reduced.
Indications and Usage
Treatment of serious or severe infections due to susceptible bacteria not treatable with other antimicrobials (eg, staphylococcus).
Treatment of pseudomembranous colitis caused by Clostridium difficile ; treatment of staphylococcal enterocolitis.
IV prophylaxis against bacterial endocarditis in penicillin-allergic patients.
Dosage and Administration
PO 500 mg to 2 g/day in 3 or 4 divided doses for 7 to 10 days.
PO 40 mg/kg/day (up to 2 g/day) in 3 or 4 divided doses for 7 to 10 days.
PO 10 mg/kg/day in divided doses.
IV 500 mg by IV infusion every 6 h or 1 g every 12 h.
IV 10 mg/kg/dose every 6 h.
Infants & Newborns
IV 15 mg/kg initially, followed by 10 mg/kg every 12 h for newborns in first week of life, and every 8 h for ages up to 1 mo.
* Prepare oral solution by adding 115 mL of water to 10 g vial or 20 mL of water to 1 g vial. Further dilute prepared oral solution dose with 30 mL of water or flavoring syrups may be used with oral solution.
* May give oral solution via nasogastric tube as indicated or ordered.
* Reconstitute parenteral form with sterile water for injection.
* Further dilute parenteral medication with compatible solution (eg, dextrose injection 5%, sodium chloride 0.9%, lactated Ringer's).
* Parenteral form may be administered by oral route.
* Reconstituted oral solution may be stored in refrigerator for 2 wk after bottle is opened.
* Dilute to minimum dilution of 2.5 mL and infuse parenteral solution over at least 60 min. Intermittent infusion preferred.
* Pretreat with antihistamine if patient has previously experienced Red Man Syndrome.
* Dosage or dosage interval may be changed based upon vancomycin serum levels.
* Reconstituted powder for injection is stable at room temperature for 2 wk.
* Dilute solutions (sodium chloride or D5W) are stable at room temperature for 24 h.
Aminoglycosides increased risk of nephrotoxicity and ototoxicity when vancomycin given with aminoglycosides
Amphotericin possible increased risk of nephrotoxicity when vancomycin given with amphotericin Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics
Anaesthetics, General hypersensitivity-like reactions can occur when intravenous vancomycin given with general anaesthetics See also Surgery and Long-term Medication, section 15.1
Capreomycin increased risk of nephrotoxicity and ototoxicity when vancomycin given with capreomycin
Ciclosporin increased risk of nephrotoxicity when vancomycin given with ciclosporin
Cisplatin increased risk of nephrotoxicity and possibly of ototoxicity when vancomycin given with cisplatin
Colestyramine effects of oral vancomycin antagonised by colestyramine Other drugs should be taken at least 1 hour before or 4-6 hours after colestyramine to reduce possible interference with absorption
Colistin increased risk of nephrotoxicity and ototoxicity when vancomycin given with colistin
Diuretics, Loop increased risk of otoxicity when vancomycin given with loop diuretics
Polymyxins increased risk of nephrotoxicity when vancomycin given with polymyxins
Suxamethonium vancomycin enhances effects of suxamethonium
Tacrolimus possible increased risk of nephrotoxicity when vancomycin given with tacrolimus Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (see section 13.5.3) does not apply to tacrolimus taken systemically
Vancomycin belongs to Antibacterials and will have the following interactions:
Oestrogens antibacterials that do not induce liver enzymes possibly reduce contraceptive effect of oestrogens (risk probably small, see section 7.3.1) Interactions of combined oral contraceptives may also apply to combined contraceptive patches; in case of hormone replacement therapy low dose unlikely to induce interactions
Rash; urticaria; pruritus; inflammation at site of injection.
Increased serum creatinine and BUN; renal failure.
Anaphylaxis; drug fever; chills; Red Man Syndrome (hypotension with or without rash over face, neck, upper chest, and extremities).
Category C .
Excreted in breast milk.
Confirming serum levels may be appropriate in newborns. Use of vancomycin with anesthetics may cause erythema and flushing.
Special Risk Patients
Use with caution in patients with preexisting hearing loss, patients receiving ototoxic or nephrotoxic drugs, patients receiving drugs that cause neutropenia; patients with renal function impairment; elderly; newborns.
Too rapid IV infusion or bolus administration may be associated with exaggerated hypotension, including shock and cardiac arrest, with or without maculopapular rash over face, neck, upper chest, and extremities (Red Man or Redneck syndrome). Reaction has been rarely associated with slow infusion or oral or intraperitoneal administration.
May occur after total dose of 25 g.
Tissue irritation, thrombophlebitis
Give by secure IV route. May minimize thrombophlebitis by giving slowly as dilute infusion.
Increase serum creatinine, increase BUN, hearing loss, ringing in ears, vertigo.
* Explain that IV medication is given at regular intervals to maintain blood levels.
* Tell patient to report hearing loss, ringing in ears, or vertigo to health care provider.
* Explain signs of superinfection (eg, vaginitis).
* Identify symptoms of potential adverse reactions.
* Tell patient to maintain adequate fluid intake.
- Basic Profile / Key Facts (3)
- Calorie chart (1)
- Calories Burned Per Minute for Various Activities (1)
- Contraindications (1)
- Description and Clinical Pharmacology (1)
- Drug Interactions (1)
- Drug Profile (13)
- Early Childhood Physical Development (1)
- Ideal Body Weight Chart (2)
- Indications and Dosage (1)
- Normal Laboratory Values (1)
- Overdosage (1)
- Side Effects and Adverse Reactions (1)
- Warnings and Precautions (1)